Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Denver news in your inbox

Catch up on the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Des Moines news in your inbox

Catch up on the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Minneapolis-St. Paul news in your inbox

Catch up on the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tampa Bay news in your inbox

Catch up on the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Charlotte news in your inbox

Catch up on the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Illustration: Sarah Grillo/Axios

The multi-hundred-billion-dollar retail prescription drugs market is the new battleground for Big Tech, relying on its usual brute force in an effort to keep growing. But in neither the U.S. nor China is it proving as easy to crack as groceries.

The big picture: In the U.S. and China, retail drugs are too big to ignore — last year, Americans spent $466.6 billion on pharmaceuticals, and the Chinese forked out $122.6 billion in a market growing at about 9% a year. That's why Amazon and China's Alibaba have piled into the sector.

The bottom line: "There's just too much money to be made," says Sophie Cairns, a pharmaceutical analyst at IHS Markit, speaking of China's massive population and a growing demand for drugs that is forecast to surpass the U.S.

In the U.S.:

  • In June, Amazon cratered the share prices of retail chains like Rite Aid and CVS when it paid $1 billion for PillPack, an on-line pharmacy licensed in all 50 U.S. states.
  • The acquisition gave Amazon an immediate perch in the much larger health care value chain ecosystem, says Steve Kraus, head of health care investing at Bessemer Venture Partners.
  • Be smart: Unlike the grocery coup Amazon achieved a year ago by buying Whole Foods, retail pharmaceuticals are fragmented and will be more difficult to dominate, writes Alex Moazed at Inc. In addition, to the degree Amazon is after the larger health care sector, it's surrounded by regulatory and compliance moats.
  • Kraus tells Axios: To keep growing, Amazon needs a stake in broader health care, which comprises 20% of U.S. GDP.

In China:

  • Alibaba's health care arm, AliHealth, is limited to selling over-the-counter pharmaceuticals because of a government ban decreed last year on online sale of prescription drugs.
  • But, but, but: There are questions about how serious the government is about the ban, and Cairns thinks retail of online prescription drugs will ultimately be permitted.

Between the lines: Both Alibaba and rival Tencent are already casting a wide nets in health care. For example ...

  • AliHealth has partnered with Merck, the German pharmaceutical company, on drug-tracking (counterfeit drugs are a big problem in China).
  • Merck will put its diabetes, cardiovascular and thyroid medicines on Alibaba's drug tracking platform, says Merck spokesperson Natalie Zhao. Then patients can scan barcodes on drug boxes for information on diseases, verification that the drugs are authentic, and reminders on when to take them.
  • Tencent is working with Miying, which says it uses AI to help doctors diagnose cancer, says Nikhil Krishnan, a senior intelligence analyst with CB Insights.

"Chinese companies do not face the same level of regulatory or infrastructural roadblocks as Amazon in the United States," Krishnan says.

Go deeper

Off the Rails

Episode 7: Trump turns on Pence

Photo illustration: Eniola Odetunde/Axios. Photos: Elijah Nouvelage, Alex Wong/Getty Images

Beginning on election night 2020 and continuing through his final days in office, Donald Trump unraveled and dragged America with him, to the point that his followers sacked the U.S. Capitol with two weeks left in his term. Axios takes you inside the collapse of a president with a special series.

Episode 7: Trump turns on Pence. Trump believes the vice president can solve all his problems by simply refusing to certify the Electoral College results. It's a simple test of loyalty: Trump or the U.S. Constitution.

"The end is coming, Donald."

The male voice in the TV ad boomed through the White House residence during "Fox & Friends" commercial breaks. Over and over and over. "The end is coming, Donald. ... On Jan. 6, Mike Pence will put the nail in your political coffin."

Big Tech's post-riot reckoning

Photo illustration: Sarah Grillo/Axios. Photo: Tasos Katopodis/Getty Images

The Capitol insurrection means the anti-tech talk in Washington is more likely to lead to action, since it's ever clearer that the attack was planned, at least in part, on social media.

Why it matters: The big platforms may have hoped they'd move to D.C.'s back burner, with the Hill focused on the Biden agenda and the pandemic out of control. But now, there'll be no escaping harsh scrutiny.

16 mins ago - Technology

Why domestic terrorists are so hard to police online

Illustration: Eniola Odetunde/Axios

Domestic terrorism has proven to be more difficult for Big Tech companies to police online than foreign terrorism.

The big picture: That's largely because the politics are harder. There's more unity around the need to go after foreign extremists than domestic ones — and less danger of overreaching and provoking a backlash.